cyrilzakka/clinical-trials huggingface dataset:
Research of Revascularization in Immature Teeth With Periapical Periodontitis

Revascularization is an alternative new treatment of immature permanent teeth with necrotic pulp nowadays while apexification is the traditional therapy. The investigators suppose that revascularization is superior to apexification at developing the root of immature permanent teeth and reducing the risk of root fracture,and the research is designed.

The investigators design to collect a group of patients presenting immature permanent teeth with periapical periodontitis in certain criterion. The investigators will divide the patients into two groups randomly. One group will get treated with revascularization while the other with apexification. The investigators want to evaluate the short-term and long-term effects of the two groups to get a conclusion of the clinical value of revascularization.

Eligibility Criteria:
Inclusion Criteria:

* clinical diagnosis of periapical periodontitis
* must be immature permanent teeth
* must be local Guangzhou

Exclusion Criteria:

* blood disease
* residual root that is advised to extract
* serious periodontitis
* women in pregnancy
The Chromatic Evaluation of Universal Nano-hybrid Composites

The goal of this clinical trial is to evaluate the preheating effect of a group shade resin-based composite. The evaluation will be done on Ryge criteria. The main question it aims to answer is if there is a difference in time between preheated and non-heated resin-based composites in the oral cavity. Participants will be given treatment for cavities class 2 on premolars and molar and will come for recall at 24h, 1 week, 6 weeks, 3 months, 6 months, and 1 year.

The participants in the study will be adult patients (over 18 years old). Each patient will receive 2 restorations on premolars or molars, class 2, and medium cavities. The restorations will be performed under isolation with rubber-dam, and restored with preheated or not-heated resin-based composite. The occlusion will be tested and they will be notified to come for recall in order to make the evaluation of the restorations.

Eligibility Criteria:
Inclusion Criteria:

* Permanent dentition
* The OHI index = 0
* Non-smoking patient
* The patient has a healthy diet
* The patient has parafunction
* The antagonist tooth is healthy / with direct restorations
* The caries are situated on proximal surfaces on premolars, molars
* The cavities have a medium depth

Exclusion Criteria:

* Temporary dentition
* The OHI index \>= 1
* The patient is smoker
* The patient has an unhealthy diet
* The patient suffers from bruxism, clenching
* The antagonist tooth has an indirect restoration
* The caries are situated on canines or incisors
* The cavities have a deep or shallow depth
A Multifaceted Intervention on Reducing Immunization Errors

The goal of this trial is to reduce the general error related to vaccines and immunizations (composited on secondary endpoint), after 11 moths of folow-up after cluster randomization and stepped wedge on primary care on brazilian public health.

The main questions it aims to answer are:

1. To evaluate the effectiveness of a multifaceted intervention in vaccination rooms in reducing vaccination errors.
2. To describe the rate of adverse events following immunization (AEFI) and the associated factors.

Researchers will compare two times in a Stepped Wedge design:

1. Usual Care :All sites will follow the standard practices for vaccine management and immunization in health units with vaccination rooms during 1 month.

   All sites will be randomized into 11 steps (corresponding to the number of stages required to complete the 12-month study). At each step, 8 clusters (each containing one immunization service within a primary care facility) will receive the intervention."
2. Multifaceted Strategy :\*This time will implement a multifaceted quality improvement and process strategy composed of:

   * Video-based training on vaccine management.
   * Development of an optimized Cold Chain Manual, streamlining guidelines for vaccine handling.
   * Technical documents providing comprehensive guidance on the appropriate management of vaccines and their respective immunization schedules.
   * Technical documentsaddressing the management of errors identified post-vaccination and offering recommendations for public guidance.

Eligibility Criteria:
Cluster Inclusion Criteria

* Health units with vaccination rooms administering at least 2,000 doses of vaccines/immunobiologicals per month,

Cluster Exclusion Criteria

* Primary health units that do not provide consistent vaccination services to the population.
DHA and Vitamin D in Children With Biopsy-proven NAFLD

Non-alcoholic fatty liver disease (NAFLD) has reached epidemic proportions and is rapidly becoming the one of most common causes of chronic liver disease in children. The pathogenesis of NAFLD is generally considered the result of a series of liver injuries, commonly referred as "multi-hit" hypothesis. Several studies suggest that inflammatory pathways and oxidative stress could be responsible of disease progression.

The purpose of this interventional study is to evaluate the efficacy and tolerability of docosahexaenoic acid (DHA) and Vitamin D in children and adolescents with biopsy-proven nonalcoholic fatty liver disease (NAFLD).

Sixty-six children or adolescents (4-16 years) with liver biopsy proven NAFLD will be enrolled. They will be randomized to treatment with DHA and Vitamin D (n=33) or an identical placebo (n=33) given orally for a period of 6 months. All patients will be included in a lifestyle intervention program consisting of a diet tailored on the individual requirements and physical exercise.

Patients will undergo a medical evaluation at 3-6 and 12 months during the 12-months study period. Liver biopsy will be performed at baseline and at 12 months. Anthropometric measurements and laboratory tests, including liver enzymes, gluco-insulinemic profile and lipids will be performed at baseline and repeated at 6-12 months

Eligibility Criteria:
Inclusion Criteria:

* biopsy consistent with the diagnosis of NAFLD/NASH
* reduced serum levels of vitamin D aminotransferases (ALT) levels \<10 upper limit of normal
* hyperechogenicity at liver ultrasound examination suggestive of fatty liver
* International normalized ratio (INR) \< 1,3
* Albumin \> 3 g/dl
* total bilirubin \< 2,5 mg/dl
* no previous gastrointestinal bleeding
* no previous portosystemic encephalopathy
* normal renal function
* no hepatitis B, hepatitis C infection
* normal cell blood count

Exclusion Criteria:

* alcohol consumption
* use of drugs known to induce steatosis or to affect body weight and carbohydrate metabolism
* autoimmune liver disease, metabolic liver disease, Wilson's disease, and a-1-antitrypsin-associated liver disease
* every clinical or psychiatric disease interfering with experimentation according to investigator's evaluation
* finding of active liver disease due to other causes
I CAN DO Surgical ACP

The goal of the Advanced Care Planning (ACP) study is to encourage patients aged 65 or older who are referred for elective surgery to have advanced care planning.

ACP is also a critical way to support older adults in participating actively with clinicians in making real-time, complex medical decisions so that the medical care they receive is aligned with their goals. Our team has designed and tested a theory-based, interactive ACP patient-facing technology solution (PREPARE) based on the new ACP paradigm of preparing people for communication and medical decision-making. The study team hypothesizes that by including PREPARE into the electronic health record (EHR)-centric pre-surgery workflow for older adults and including automated reminders, the study team can empower patients and surgical teams to engage in ACP discussions.

Participants will be randomized to Arms: (1) Letter about ACP, PREPARE advanced directive (AD), PREPARE website; (2) Letter, advanced directive (AD), PREPARE plus reminder messages; (3) Letter, advanced directive (AD,) PREPARE plus reminders plus a healthcare navigator on ACP documentation (clinically meaningful ACP, primary outcome). All patients randomized to the intervention will be sent a patient-reported ACP engagement survey (secondary outcome).

Eligibility Criteria:
Inclusion Criteria:

- Older Adults (age 65+) referred for surgical evaluation

Exclusion Criteria:

1. ACP on file within 3 years prior to surgery (UCSF and UCI) and 5 years (UMN)
2. Was previously randomized into intervention for a prior surgery during the 18-month study period
Impact of Diet and Nutrition on Growth and Development in Young Children

The association between nutrition in early life and its long-term health consequences has long been known. However, there is a scarcity of scientific evidence on how nutritional status affects child growth and development in remote, rural agro-pastoral communities with distinct dietary intake habits, geographical location, socio-economic status, and cultures.

Childhood malnutrition is endemic in Pakistan. However, the agro-pastoral communities of Pakistan are at particularly high risk of childhood malnutrition due to low socioeconomic status, hard-to-reach geographic locations, harsh weather, and frequent natural disasters due to rapid climate change. Furthermore, distinct dietary habits and cultures may also influence child nutritional status and health and development in these communities. The present study aims to assess the dietary intake/patterns, nutritional status, and their association with the growth and development of children from remote, agro-pastoral communities of District Swat, Pakistan.

In this prospective cohort study from Pakistan, infants and young children (n=416) aged ≤ 2 years and residing in agro-pastoral communities of District Swat will be recruited and followed every 12 months for 5 years. An age and gender-matched comparison group of children (n=416) will also be recruited from the more urban areas of District Swat. Data on household socio-economic status, Household Food Insecurity Access Scale (HFIAS), Minimum Dietary Diversity (MDD) of Mothers, Infant and young child feeding practices (IYCF), Complimentary Feeding and Eating practices, and growth and development of the children will be assessed from baseline and every 12 months till the child is 5 years old. Anthropometric assessment including height, weight, mid-upper arm circumference (MUAC), and BMI will also be performed at each time point.

Eligibility Criteria:
Inclusion Criteria:

* Households living in the area from the last two 2 years.
* Households having infants or young children ≤ years.
* Households planning to reside in the same area for the next 1 year.

Exclusion Criteria:

* Children with any co-existent systemic diseases, confirmed from medical records.
* Children on continuous medications for any medical issue.
* Physically or mentally handicapped children
RFA for Small HCC With No-touch Technique Using Octopus Electrode

In this study, the investigators are going to prospectively compare the clinical outcomes (technical success rate, 12 month local tumor progression rate, complication rate, tumor seeding rate) of Radiofrequency ablation (RFA) with octopus electrode and no-touch technique for Hepatocellular carcinoma (HCC) to those of RFA with conventional tumor puncture method with the same device.


Eligibility Criteria:
Inclusion Criteria:

* Child-Pugh class A
* patient with 1cm-2.5cm sized HCC
* 1 or 2 HCCs
* being referred for curative purpose of RFA
* sign informed consent

Exclusion Criteria:

* maximum tumor diameter greater than 2.5cm
* Child-Pugh class B or C
* more than 3 HCC lesions
* invisible tumor even after US/CT or US/MR fusion
* presence of vascular tumor thrombosis or extrahepatic metastasis
* severe coagulopathy (PLT \< 50K, PT \< 50% of normal range)
Do Furanocoumarins Mediate the Fexofenadine-grapefruit Juice Interaction?

Purpose: Grapefruit juice is one of the most extensively studied dietary/natural substances shown to interact with a variety of medications. However, unanswered questions remain regarding the causative ingredients and mechanisms underlying such drug-grapefruit juice interactions. Compounds in grapefruit juice called furanocoumarins have been established as major causative ingredients, which act by inhibiting the elimination (metabolism) of drugs, leading to increased circulating drug concentrations. Increased drug concentrations can in turn lead to increased drug potency or even toxicity. Grapefruit juice also has been shown, paradoxically, to decrease circulating concentrations of some drugs, including the non-sedating antihistamine agent, fexofenadine (Allegra), which undergoes negligible metabolism. Whether or not furanocoumarins mediate the decrease in fexofenadine concentrations is unknown. The purpose of the proposed study is to compare the effects of a "furanocoumarin-free" grapefruit juice with grapefruit juice on circulating concentrations of fexofenadine.

Participants: Healthy volunteers of any race/ethnicity, ranging in age from 18 to 65 years, will be enrolled.

Procedures (methods): Procedures will include administration of water, furanocoumarin-free grapefruit juice, or grapefruit juice with fexofenadine; placement of an intravenous (IV) line; and collection of blood over 72 hours.

Eligibility Criteria:
Inclusion Criteria:

* Men or women between the ages of 18 and 65
* Normal screening laboratory test results
* Able to understand the informed consent form
* Willing to abstain from grapefruit products and all fruit juices for one week prior to and during the study
* Willing to abstain from alcohol and caffeinated beverages the evening prior to each study day

Exclusion Criteria:

* History of intolerance to grapefruit products
* History of any allergy or hypersensitivity to grapefruit products or fexofenadine
* History of significant medical conditions that the study physician believes would increase risk
* History of significant alcohol abuse and/or illicit drug use
* Tobacco use within the month preceding the study
* Pregnancy or breast-feeding
* Taking concomitant medications, both prescription and non-prescription (including herbal products), known to alter fexofenadine blood levels or P-gp and/or OATP activity (women stabilized on hormonal methods of birth control will be allowed to participate)
The Prevention of Erythropoietin on Cardiac Surgery-associated Acute Kidney Injury

To testify the prevention of Erythropoietin on cardiac surgery associated-acute kidney injury, and trying to provide evidence for protecting the renal function and improving the prognosis for patients after cardiac surgery.

Patients meet the inclusion criteria and agree to sign an informed consent will be randomly assigned into the control group or erythropoietin group.Interventions will be applied 1 day(24hrs) before the cardiac surgery. Blood and Urine samples will be collected after the surgery. By using the criterion given by KDIGO2012 and testing the biomarkers for acute kidney injury, we hope to find out if there is an association between erythropoietin administration and the occurence of acute kidney injury.

Eligibility Criteria:
Inclusion Criteria:

1. Preoperative hemoglobin\<130g/L;
2. Surgery: valve, coronary artery bypass graft or surgery for congenital heart diseases;
3. Volunteers with informed consent.

Exclusion Criteria:

1. Patients combined with infection;
2. Patients with end-stage renal disease and undergoing renal replacement therapy
3. Patients with the history of thromboembolism;
4. Patients with malignant tumor and undergoing chemotherapy;
5. Patients with unmanageable hypertension (systolic pressure\>200 mmHg or diastolic pressure\>110mmHg);
6. Patients allergic to erythropoietin;
7. Patients injected erythropoietin within 2 weeks.
Effect of Intake of Glycin Max (L.) Merr. Peel Extract on Body Fat and Body Weight

The investigators performed a 8-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Glycin max (L.) Merr. peel extract on decrement of body fat. The investigators measured decrement of body fat parameters , including Body Fat Mass, Percent Body Fat, weight and BMI(body mass index), and monitored their blood pressure.


Eligibility Criteria:
Inclusion Criteria:

* Males and females 19-65 years old
* BMI(body mass index) ≥ 25 kg/m\^2 or WC(Waist Circumference) ≥ 90(men), WC ≥ 85(women)
* Able to give informed consent

Exclusion Criteria:

* Significant variation in weight(more 10%) in the past 3 months
* Allergic or hypersensitive to any of the ingredients in the test products
* History of reaction to any of the test products or of gastrointestinal diseases such as Crohn's disease or gastrointestinal surgery
* History of alcohol or substance abuse
* Participation in any other clinical trials within past 2 months
* Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study
* Pregnant or lactating women etc.
Vitamin D and Staphylococcus Aureus in the Diabetes Study

There are indications that the vitamin D status of an individual is related to susceptibility to staphylococcal infections. In the present study we will examine nasal colonisation rate in subjects participating in an ongoing vitamin D intervention study ( 20.000 IU cholecalciferol per week vs placebo) for the prevention of type 2 diabetes in subjects with impaired glucose tolerance.


Eligibility Criteria:
Inclusion Criteria:

* participant in an ongoing intervention study with vitamin D

Exclusion Criteria:

* none specifically for this study
Efficacy and Safety of COVID-19 Vaccine in Cancer Patients

This study gathers information about how a cancer patient responds to COVID-19 vaccine during cancer treatment compared to healthy individuals. The information gained may help determine how effective currently available COVID-19 vaccines are in cancer patients receiving chemotherapy and learn more regarding how long an immune response will last compared to healthy individuals.

PRIMARY OBJECTIVES:

I. To determine the antibody response to COVID-19 vaccine after vaccination. II. To assess the adverse events of COVID-19 vaccines in cancer patients. III. To determine the incidence and severity of COVID-19 infection after the vaccination.

OUTLINE:

Patients undergo blood sample collection at baseline (prior to first COVID-19 vaccination), prior to second vaccination, 1, 6, and 12 months after the last vaccination. Patients receiving a booster vaccine will undergo blood collection prior to and 1-3 months after vaccination. Patients who receive the types of COVID-19 vaccines that do not require the second injection skip blood sample collection at this time point. This study will collect information regarding the type of COVID-19 vaccine received, date of vaccine injection, and any side effects associated with the COVID-19 vaccine that trial participant encountered. This study will also review the medical record for outcomes and information related to the blood testing.

Eligibility Criteria:
Inclusion Criteria:

* Willing to receive COVID-19 vaccination as per standard of care or has already received one or both COVID-19 vaccine injections as long as it has not been longer than three months since their second injection (or the only injection if they receive the types of COVID019 vaccines that do not require the second injection)
* Willing and able to provide research blood samples
* Capable of providing valid informed consent
* For cancer patient cohort:

  * Male or female age \>= 18 years
  * Histologically confirmed solid malignancy on or will be starting on systemic cytotoxic chemotherapy
* For healthy individual cohort:

  * Male or female age \>= 18 years
  * No history of active malignancy =\< 3 years
* EXCEPTIONS: Adequately treated non-melanotic skin cancer (adequate wound healing is required prior to study entry) or carcinoma-in-situ of the cervix
* NOTE: If there is a history of prior solid tumor malignancy, it must have been treated curatively with no evidence of recurrence =\< 3 years
* PATIENTS WITH PREVIOUS COVID-19 INFECTION: Willing and able to provide research blood samples
* PATIENTS WITH PREVIOUS COVID-19 INFECTION: Capable of providing valid informed consent
* PATIENTS WITH PREVIOUS COVID-19 INFECTION: Male or female age \>= 18 years
* PATIENTS WITH PREVIOUS COVID-19 INFECTION: Previous history of COVID-19 infection with positive SARS-CoV-2 ribonucleic acid (RNA) by polymerase chain reaction (PCR) or anti-SARS-CoV-2 nucleocapsid antibody

Exclusion Criteria:

* Immunocompromised patients including patients known to be human immunodeficiency virus (HIV) positive or those on immunosuppressive therapy other than chemotherapy in the judgment of the investigator
Effects of Myofascial Release and Neuromuscular Training for Pes Anserine Syndrome Associated With Knee Osteoarthritis

A randomized control trial will be conducted at the outpatient department of Dow Institute of Physical Medicine and Rehabilitation. A sample size of 80 is calculated using PASS version 11 software. The subjects will be first screened and those who fulfill the inclusion criteria, will be asked to fill the consent form. After selection, the participants will be randomly allocated by the help of computer generated randomization sheet, into two groups i.e. experimental and the control group. The group A will be provided with the myofascial release along with the neuromuscular training whereas the group B will only receive the neuromuscular training. Cold pack will be applied to both the groups. The neuromuscular training consists of warm-up phase, lunges, sideways exercises, wall squats, weight transfer exercises, step up and down and the cool down phase. Total 12 sessions of 35 minutes each will be given to all the participants for about 4 weeks on alternate days. Outcome measures will be analyzed by visual analogue scale (VAS) for pain assessment, goniometry for range of motion and the Knee injury and Osteoarthritis Outcome Score (KOOS) to evaluate the functional assessment of the patients at the baseline and the post intervention.


Eligibility Criteria:
Inclusion Criteria:

* Male and Females both with the age between 40-60 years.
* Patients with unilateral or bilateral knee osteoarthritis with pes anserine syndrome.
* Patients with knee pain more than 3.4 cm on visual analogue scale as minimum cut of value.
* Kellgren and Lawrence grade II and III on radiological findings.
* Duration of knee osteoarthritis more than 3 months (chronic).

Exclusion Criteria:

* Patients with any neurological disorder.
* Knee deformities such as contractures, genu valgum and genu varum.
* Septic knee arthritis.
* History of ligamentous injury or meniscal tear.
* Cancer or any other malignancy or bone tumor.
* Any history of previous lower limb arthroplasty or other knee surgery.
* Comorbid like diabetes mellitus.
* Inflammatory rheumatic disease (R.A).
Radiation Dosimetry in Teeth

Irradiation of any tissue creates changes in that tissue. Ionizing radiation imparts charges to the tissue as it interacts with tissue components, changing the tissue structure. The specific type of modification also depends to some extent upon the type of tissue irradiated. It has been shown that it is possible to read the tooth enamel irradiation record using techniques such as electron paramagnetic resonance (EPR), or electron spin resonance (ESR).

It is proposed to examine radiation responses in approximately one hundred (100) human teeth. This would include teeth free of, as well as those containing, amalgam (silver) restorations. For the first group, teeth that have already been collected (pre-existing pathological specimens) would be used. These teeth were surgical/pathological discards collected without identifiers by the dental providers.


Eligibility Criteria:
Inclusion Criteria:

* Discarded pathologic specimens (teeth)